The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization

Keane, Colm, Gibbs, Simon, Seymour, John F., Mills, Anthony K ., Grimmett, Karen, Van Kuilenberg, Rosita, Russell, Saal, Gill, Devinder, Prince, H. Miles, Marlton, Paula and Mollee, Peter (2006) The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization. Hematological Oncology, 24 3: 159-163. doi:10.1002/hon.784


Author Keane, Colm
Gibbs, Simon
Seymour, John F.
Mills, Anthony K .
Grimmett, Karen
Van Kuilenberg, Rosita
Russell, Saal
Gill, Devinder
Prince, H. Miles
Marlton, Paula
Mollee, Peter
Title The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization
Journal name Hematological Oncology   Check publisher's open access policy
ISSN 0278-0232
1099-1069
Publication date 2006-09-01
Sub-type Article (original research)
DOI 10.1002/hon.784
Volume 24
Issue 3
Start page 159
End page 163
Total pages 4
Editor Francesco Bertoni
Place of publication Chichester, United Kingdom
Publisher John Wiley & Sons
Language eng
Subject 110202 Haematology
Abstract he Hyper-CVAD chemotherapy regimen is being increasingly applied to a number of haematological malignancies. We assessed the impact of Hyper-CVAD on peripheral blood stem cell (PBSC) yields and examined the optimal timing of PBSC collection when using this regimen. Seventy-four consecutive patients were identified in whom an attempt was made to collect PBSC, usually on recovery from cycle A or B. Where PBSC collection was attempted after cycle 3B, only 18% (3/17) of patients successfully mobilized. Fifty-seven patients were mobilized on recovery from cycle 1B (n = 13), 2A (n = 22), 2B (n = 14) or 3A (n = 8). Compared with cycle 2A, 1B was not superior in achieving the minimum of 2 × 106/kg CD34+ cells (100% vs. 77%, p = 0.13), but was superior in terms of total CD34+ yield (21.4 vs. 3.2 × 106/kg, p < 0.001), achieving the target CD34+ cell count of 5 × 106/kg (92% vs 36%, p = 0.002), and obtaining both a minimum (92% vs. 18%, p < 0.001) and target (77% vs. 0%, p < 0.001) graft with a single apheresis. There were no significant differences in PBSC yields following cycles 2A, 2B and 3A. Hyper-CVAD has substantial stem cell toxicity which can be readily circumvented by using the early chemotherapy cycles for mobilization. Copyright © 2006 John Wiley & Sons, Ltd.
Keyword Haematological malignancy
Hyper-CVAD chemotherapy
Stem cell mobilization
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ
Additional Notes Published Online: 15 Jun 2006

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 16 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 12 Jan 2010, 20:18:57 EST by Natalie Holt on behalf of Faculty Of Health Sciences